AWS makes $20M move to counter COVID-19 with compute power

Amazon Web Services is corralling the expertise of more than 30 research institutions, businesses and startups to help combat COVID-19. The cloud giant has allotted $20 million for the work.  

Calling the effort the AWS Diagnostic Development Initiative, the Amazon subsidiary says it will use the set-aside to fund its project partners—all AWS customers—through in-kind credits and technical support.

According to an AWS blog post, the idea for the initiative was born of several primary unmet needs evident in the global COVID-19 outbreak.

These include accurate disease detection (“the tip of the spear for any effective pandemic response strategy”), diagnostics research (which “has historically been underfunded and largely deprioritized in favor of a focus on vaccine”) and reliable, scalable compute power for organizations working on disease diagnostics.

Commenting on the latter, the blogger, AWS exec Teresa Carlson, says the initiative can deliver such power coupled with associated services like analytics and machine learning to help process and analyze large datasets with speed and precision.

The program will be open to accredited research institutions and private entities that are using AWS to support research-oriented workloads for the development of point-of-care diagnostics, Carlson writes.

“Given the need,” she adds, “the emphasis initially will be on COVID-19, but we will also consider other infectious disease diagnostic projects.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.